Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids

Chest

Volumn 119, Issue 4, 2001, Pages 1021-1026

  Wilson, A M ^a   Dempsey, O J ^a   Sims, E J ^a   Lipworth, B J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Adenosine monophosphate; Inhaled corticosteroids; Montelukast; Nitric oxide; Salbutamol; Symptoms

Indexed keywords

ADENOSINE PHOSPHATE; CORTICOSTEROID; MONTELUKAST; NITRIC OXIDE; PLACEBO; SALMETEROL;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BLOOD CELL COUNT; BRONCHODILATATION; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE COURSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG SCREENING; EOSINOPHIL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MALE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

EID: 0034924293     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.119.4.1021     Document Type: Article

References (36)

1. Modern drug treatment of chronic asthma
2. Effect of inhaled formoterol and budesonide on exacerbations of asthma
3. Potential masking effects of salmeterol on airway inflammation in asthma
4. Effects of treatment with formoterol on bronchoprotection against methacholine
5. Bronchodilator subsensitivity to inhaled salbutamol after twice daily salmeterol in asthmatic patients
6. Inhaled corticosteroids do not prevent the development of tolerance to the broncho-protective effect of salmeterol
7. Subsensitivity to bronchopro-tection against adenosine monophosphate challenge after regular once daily formoterol
8. Leukotriene-receptor antagonists
9. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid: The Tokyo Joshi-Idai Asthma Research Group
10. Randomized, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients
11. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma
12. Additive broncho-protective and bronchodilator effects with single doses of salmeterol and montelukast in asthmatic patients receiving inhaled corticosteroids
13. Adenosine bronchoprovocation: A promising marker of allergic inflammation in asthma?
14. Greater effect of inhaled budesonide on adenosine 5′-monophosphate-induced than on sodium-metabisulfite-induced bronchocon-striction in asthma
15. Measuring exhaled nitric oxide: Not only a matter of how-but also why-should we do it?
16. Peripheral blood markers: Evaluation of inflammation in asthma
17. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma
18. Loss of normal cyclical β2-adrenoceptor regulation and increased premenstrual responsiveness to adenosine monophosphate in stable female asthmatics
19. Increased exhaled nitric oxide in asthma is mainly derived from the lower respiratory tract
20. Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction
21. Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction
22. Airway subsensitivity with long-acting β2-agonists: Is there cause for concern?
23. Effect of β-agonists on airway effector cells
24. 2-adrenoceptor
25. Differential effects of formoterol on adenosine monophosphate and histamine reactivity in asthma
26. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction
27. The effect of inhaled fluticasone propionate (FP) 100 μg bd compared with oral zafirlukast 20 mg bd on bronchial hyperresponsiveness in mild to moderate asthmatics
28. Effect of treatment with zafirlukast (ACCOLATE) on bronchial hyperresponsiveness in patients with mild-to-moderate asthma
29. Effect of a leukotriene antagonist, ONO-1078, on bronchial hyperresponsiveness in patients with asthma
30. Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma
31. Clinical control and histopathologic outcome of asthma when using airway hyper-responsiveness as an additional guide to long-term treatment
32. Allergen challenge increases cell traffic between bone marrow and lung
33. Montelukast, a cysteinyl leukotriene receptor antagonist, decreases blood eosinophils and improved signs and symptoms of asthma over a 3-month period
34. Anti-inflammatory effects of salmeterol compared with beclomethasone in eosinophilic mild exacerbations of asthma: A randomized, placebo controlled trial
35. The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma
36. Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma